Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone949-481-9825
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual Sales$2.08 million
Price / Sales0.14
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions
What is Aeolus Pharmaceuticals' stock symbol?
Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."
How were Aeolus Pharmaceuticals' earnings last quarter?
Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. View Aeolus Pharmaceuticals' Earnings History.
Has Aeolus Pharmaceuticals been receiving favorable news coverage?
News articles about AOLS stock have trended negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aeolus Pharmaceuticals earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Aeolus Pharmaceuticals' key competitors?
Some companies that are related to Aeolus Pharmaceuticals include Capstone Therapeutics (CAPS), Cotinga Pharmaceuticals (COTQF), GlobeImmune (GBIM), Spotlight Innovation (STLT), Affymax (AFFY), FutureWorld (FWDG), Myrexis (MYRX), Tetralogic Pharmaceuticals (TLOG), HST Global (HSTC), Targeted Medical Pharma (TRGM), Orexigen Therapeutics (OREXQ), Poniard Pharmaceuticals (PARD), Inspyr Therapeutics (NSPX), Epirus Biopharmaceuticals (EPRSQ) and Tianyin Pharmaceutical (TPIY).
Who are Aeolus Pharmaceuticals' key executives?
Aeolus Pharmaceuticals' management team includes the folowing people:
- Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 50)
- Mr. John L. Mcmanus, Chief Exec. Officer and Pres (Age 55)
- Mr. Christopher Stanley, VP of Operations
How do I buy shares of Aeolus Pharmaceuticals?
Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeolus Pharmaceuticals' stock price today?
One share of AOLS stock can currently be purchased for approximately $0.0019.
How big of a company is Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals has a market capitalization of $290,000.00 and generates $2.08 million in revenue each year.
What is Aeolus Pharmaceuticals' official website?
How can I contact Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]
MarketBeat Community Rating for Aeolus Pharmaceuticals (OTCMKTS AOLS)
MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
